TNBC has the highest death rate (5-year survival 8–16%) of all breast cancer subtypes and is characterized by a lack of common therapeutic targets like estrogen receptor (ER−), progesterone receptor (PR−), and human epidermal growth factor receptor 2 (HER2−). This evidence concerns the gene ERBB2 and breast cancer.